Skip to content
The Policy VaultThe Policy Vault

Jakafi (ruxolitinib tablets) — Cigna

Myelofibrosis (Primary, Post-Polycythemia Vera, Post-Essential Thrombocythemia)

Initial criteria

  • Patient age ≥ 18 years

Approval duration

1 year